Aegros
Aegros is at the forefront of plasma fractionation, specializing in the production of high-quality, plasma-derived therapeutics. One of the company’s key offerings is HaemaFrac, a purified human plasma-derived clotting factor concentrate designed to treat bleeding disorders. Using advanced plasma fractionation techniques, Aegros extracts and purifies critical proteins from human plasma to create safe and effective treatments for conditions such as hemophilia and other bleeding disorders.
Aegros applies cutting-edge biotechnology to ensure that its fractionation process meets the highest safety and quality standards. The company’s commitment to excellence in plasma fractionation helps to deliver life-saving therapies that improve patient outcomes. By focusing on innovation and precision, Aegros continues to make a significant impact on the healthcare industry, offering essential treatments for those with complex medical needs.
Key Features of Aegros:
- • Innovative Technology – Aegros employs HaemaFrac®, a membrane-based electrophoresis process, for efficient and high-yield plasma fractionation.
- • Enhanced Production – Aegros delivers increased purity and yield of therapeutic plasma proteins compared to traditional methods.
- • National Self-Sufficiency – Aegros focuses on bolstering domestic production of essential plasma-derived medicines.
- • Hyperimmune Specialization – Aegros specializes in the production of hyperimmune therapies for critical disease treatment.
- • Sustainable Processing – Aegros utilizes an environmentally friendly, solvent-free plasma fractionation process.
Team
Professor Hari Nair
Founding Executive Chair
Mr. John Manusu
Founding Managing Director
Ms Janet Bowen
Executive Director & Chief RAQA Officer
Mandate
Health Tech
VC/ Private Equity
40 million AUD
Key Features of Aegros:
- • Limited Access to Plasma-Derived Therapies: Many patients with rare and chronic diseases struggle to access essential plasma-derived treatments due to supply shortages and high costs. Aegros aims to improve availability by utilizing advanced plasma fractionation techniques to produce high-quality therapies efficiently.
- • Quality and Safety Concerns in Plasma Products: Ensuring the safety and efficacy of plasma-derived therapies is a major challenge in the biopharmaceutical industry. Aegros addresses this by implementing rigorous quality control processes and innovative technology to deliver safe, consistent, and effective treatments.
- • Unmet Medical Needs for Rare Diseases: Patients with conditions such as bleeding disorders and immune deficiencies often face limited treatment options. Aegros focuses on developing targeted therapies to provide better solutions and improve patient outcomes.
- • Inefficiencies in Traditional Plasma Fractionation: Conventional plasma fractionation methods can be costly and inefficient, leading to wasted resources and long production cycles. Aegros utilizes cutting-edge technology to streamline the process, making it more cost-effective and scalable.
- • Sustainability and Ethical Challenges in Biopharmaceuticals: The industry faces growing concerns about ethical sourcing, sustainability, and environmental impact. Aegros prioritizes ethical and sustainable practices, ensuring responsible production and distribution of its therapies while minimizing environmental impact.
Competitive Advantages of Aegros:
- • Innovative Plasma Fractionation Technology: Aegros utilizes advanced plasma fractionation techniques, enabling more efficient and cost-effective production of plasma-derived therapies. This innovation allows the company to produce high-quality treatments while minimizing waste and improving scalability.
- • Superior Quality and Safety Standards: The company adheres to rigorous quality control and safety measures, ensuring that its plasma-derived products meet the highest industry standards. This commitment to excellence builds trust among healthcare providers and patients.
- • Focus on Unmet Medical Needs: Aegros specializes in developing therapies for rare and complex diseases, addressing gaps in treatment options for conditions such as bleeding disorders and immune deficiencies. By prioritizing these underserved areas, the company strengthens its market position.
- • Cost-Effective and Scalable Solutions: Unlike traditional plasma fractionation methods, Aegros’ approach is designed for efficiency and affordability. This allows for a more sustainable supply of critical therapies, making treatments more accessible to patients worldwide.
- • Commitment to Ethical and Sustainable Practices: Aegros integrates sustainability and ethical sourcing into its operations, ensuring responsible production and distribution. This approach not only meets regulatory requirements but also enhances the company’s reputation as a responsible leader in the biopharmaceutical industry.
Invest
GENERAL ADVICE WARNING: Being general advice, these Investment Opportunities do not take into account your objectives, financial situation, or needs. Before acting on any of these referrals you should therefore consider the appropriateness of this referral having regard to your situation. We recommend you obtain financial, legal, and taxation advice before making any financial investment decision. You should obtain, read, and understand all the relevant product disclosure statements or offer documents before investing in any financial product. Rodller is not a financial advisor. We disclose public information and the final decision as well as due diligence is between the investor and the investee.
Rodller Pte Ltd and each of their respective directors, officers, and agents believe that the information contained in this message and its attachments have been obtained from reliable sources and that any estimates, opinions, or conclusions, are reasonably held at the time of compilation. No warranty is made as to the accuracy of the information on this website and, to the maximum extent permitted by law, Rodller Pte Ltd disclaims all liability for any loss or damage which may be suffered by any transaction through relying on anything contained or omitted from this website.
Singapore Office
Center Singapore HQ
Rodller Pte. Ltd160 Robinson Road,
14-04, Singapore
068914
UEN 202125442C
Rodller Pte. Ltd160 Robinson Road,
14-04, Singapore
068914
UEN 202125442C
Copyright | All Rights Reserved Rodller 2025
